In the News

Check back regularly for the latest news and announcements regarding Coyne Scientific, its latest scientific breakthroughs, its services, and its people.

SEPTEMBER 27, 2018: COYNE SCIENTIFIC TO OFFER WORLD’S FIRST COMMERCIALLY-AVAILABLE “CLINICAL TRIALS IN A DISH” AT SAFETY PHARMACOLOGY SOCIETY’S 2018 ANNUAL MEETING

ATLANTA – September 27, 2018 Coyne Scientific, LLC (Atlanta, GA) announced today that it will offer the world’s first commercially-available “Clinical Trials in a Dish” at the Safety Pharmacology Society’s 2018 Annual Meeting, which runs from October 1-3 in Washington, DC. What exactly does the company mean by “Clinical Trials In A Dish”? According to […]

Posted in Conference Presentations | Leave a comment

SEPTEMBER 3, 2018: SLAS DISCOVERY’S SEPTEMBER, 2018 COVER STORY IS GROUND-BREAKING ARTICLE, “CLINICAL TRIALS IN A DISH: A PERSPECTIVE ON THE COMING REVOLUTION IN DRUG DEVELOPMENT”

ATLANTA – September 3, 2018

SLAS Discovery, a leading peer-reviewed scientific journal, today released its September, 2018 edition (Volume 23 Issue 8, September 2018), choosing as its cover story a ground-breaking new article titled, “Clinical Trials in a Dish: A Perspective on the Coming Revolution in Drug Development”. Copies of the article – which describes a novel drug safety testing paradigm that bridges the worlds of preclinical testing and clinical trials – can be accessed for free on the publisher’s website at: http://journals.sagepub.com/doi/full/10.1177/2472555218775028.

According to the article – which was co-authored by Bernard Fermini, PhD; Coyne Scientific CEO, Kevin P. Coyne; and Coyne Scientific President, Shawn T. Coyne – the cost of developing new drugs has reached unsustainable levels, fueled in large part by high attrition rates in clinical development. Recent studies have shown that individual drug susceptibility in a population of volunteers with unknown genetic background can be recapitulated in human induced pluripotent stem cells (hiPSCs) derived from these same individuals, providing a proof of concept for in vitro preclinical trials, and enabling cell-based screening for safety and toxicity at the level of a population, similar to clinical trials. This new platform, termed “Clinical Trials in a Dish”, or CTiD, allows researchers to define the incidence and distribution of effects of drugs (whether beneficial or adverse) across a population long before actual clinical trials, so that a pharma company can curtail development of “future failures” early on while continuing development of safe compounds that might not have met traditional safety margins.

CTiD studies, which first became commercially available earlier this year, can also help pharma companies address such important issues as repurposing shelved compounds, reducing adverse drug-drug interactions, protecting underserved ethnic populations, and protecting children and geriatric patients – economically, and without regulatory complications.

To discover how this new platform offers the potential to revolutionize safety and toxicity testing of new drugs, and/or for more information on Coyne Scientific and its services, please contact Shawn T. Coyne, President, at scoyne@coynesci.com.

* * *

Posted in Publications | Leave a comment

JUNE 4, 2018: SLAS DISCOVERY PUBLISHES GROUND-BREAKING NEW ARTICLE – “CLINICAL TRIALS IN A DISH: A PERSPECTIVE ON THE COMING REVOLUTION IN DRUG DEVELOPMENT”

ATLANTA – June 4, 2018

SLAS Discovery, a leading peer-reviewed scientific journal, today announced the publication of a ground-breaking new article by Coyne Scientific co-authors Bernard Fermini, Ph.D., Kevin P. Coyne, MBA and Shawn T. Coyne, MBA titled, “Clinical Trials in a Dish: A Perspective on the Coming Revolution in Drug Development”. The article – which describes a novel drug safety testing paradigm that bridges the worlds of preclinical testing and clinical trials – can be accessed for free ahead-of-print on the publisher’s website at: http://journals.sagepub.com/doi/full/10.1177/2472555218775028.

According to Bernard Fermini, Chief Scientific Officer: “The cost of developing new drugs has reached unsustainable levels, fueled in large part by high attrition rates in clinical development. Recent studies have shown that individual drug susceptibility in a population of volunteers with unknown genetic background can be recapitulated in human induced pluripotent stem cells (hiPSCs) derived from these same individuals, providing a proof of concept for in vitro preclinical trials, and enabling cell-based screening for safety and toxicity at the level of a population, similar to clinical trials. This new platform, termed “Clinical Trials in a Dish”, or CTiD, allows researchers to define the incidence and distribution of effects of drugs (whether beneficial or adverse) across a population long before actual clinical trials, so that a pharma company can curtail development of ‘future failures’ early on while continuing development of safe compounds that might not have met traditional safety margins.”

Added Kevin Coyne, CEO: “CTiD studies, which first became commercially available earlier this year, can also help pharma companies address such important issues as repurposing shelved compounds, reducing adverse drug-drug interactions, protecting underserved ethnic populations, and protecting children and geriatric patients – economically, and without regulatory complications.”

To discover how this new platform offers the potential to revolutionize safety and toxicity testing of new drugs, and/or for more information, please contact Shawn Coyne, President, at scoyne@coynesci.com.

* * *

Posted in Publications | Leave a comment

FEBRUARY 15, 2018: COYNE SCIENTIFIC TO UNVEIL WORLD’S FIRST COMMERCIALLY-AVAILABLE “CLINICAL TRIALS IN A DISH” AT SOCIETY OF TOXICOLOGY’S ANNUAL MEETING

ATLANTA – February 15, 2018 Coyne Scientific, LLC (Atlanta, GA) announced today that it will unveil the world’s first commercially-available “Clinical Trials In A Dish” at the Society of Toxicology’s 2018 Annual Meeting, which runs from March 11-15 in San Antonio, TX. What does the company mean by “Clinical Trials In A Dish”? According to […]

Posted in Conference Presentations | Leave a comment

OCTOBER 24, 2017: COYNE SCIENTIFIC HIGHLIGHTED IN RESEARCH & INNOVATION SESSION AT THE GEORGIA BIO SUMMIT

ATLANTA – October 24, 2017 Coyne Scientific was selected to present on a panel of three speakers discussing “Research & Innovation: Leveraging Stem Cells to Generate Scientific Breakthroughs and Stimulate Economic Development in Georgia: Game-Changing News“. CEO Kevin Coyne and Sr. Director of Data Science & Operations Eli Fine Ph.D. will be at the Georgia […]

Posted in Conference Presentations | Leave a comment